Identification and Patient Benefit Evaluation of Machine Learning Models for Predicting 90-Day Mortality After Endovascular Thrombectomy Based on Routinely Ready Clinical Information.
{"title":"Identification and Patient Benefit Evaluation of Machine Learning Models for Predicting 90-Day Mortality After Endovascular Thrombectomy Based on Routinely Ready Clinical Information.","authors":"Andrew Tik Ho Ng, Lawrence Wing Chi Chan","doi":"10.3390/bioengineering12050468","DOIUrl":null,"url":null,"abstract":"<p><p>Endovascular thrombectomy (EVT) is regarded as the standard of care for acute ischemic stroke (AIS) patients with large vessel occlusion (LVO). However, the mortality rates for these patients remain alarmingly high. Dependable mortality prediction based on timely clinical information is of great importance. This study retrospectively reviewed 151 patients who underwent EVT at Pamela Youde Nethersole Eastern Hospital between 1 April 2017, and 31 October 2023. The primary outcome of this study was 90-day mortality after AIS. The models were developed using two feature selection approaches (model I: sequential forward feature selection, model II: sequential forward feature selection after identifying variables through univariate logistic regression) and six algorithms. Model performance was evaluated by using external validation data of 312 cases and compared with three traditional prediction scores. This study identified support vector machine (SVM) using model II as the best algorithm among the various options. Meanwhile, the Houston Intra-Arterial recanalization 2 (HIAT2) score surpassed all algorithms with an AUC of 0.717. However, most algorithms provided a greater net benefit than the traditional prediction scores. Machine learning (ML) algorithms developed with routinely available variables could offer beneficial insights for predicting mortality in AIS patients undergoing EVT.</p>","PeriodicalId":8874,"journal":{"name":"Bioengineering","volume":"12 5","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/bioengineering12050468","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Endovascular thrombectomy (EVT) is regarded as the standard of care for acute ischemic stroke (AIS) patients with large vessel occlusion (LVO). However, the mortality rates for these patients remain alarmingly high. Dependable mortality prediction based on timely clinical information is of great importance. This study retrospectively reviewed 151 patients who underwent EVT at Pamela Youde Nethersole Eastern Hospital between 1 April 2017, and 31 October 2023. The primary outcome of this study was 90-day mortality after AIS. The models were developed using two feature selection approaches (model I: sequential forward feature selection, model II: sequential forward feature selection after identifying variables through univariate logistic regression) and six algorithms. Model performance was evaluated by using external validation data of 312 cases and compared with three traditional prediction scores. This study identified support vector machine (SVM) using model II as the best algorithm among the various options. Meanwhile, the Houston Intra-Arterial recanalization 2 (HIAT2) score surpassed all algorithms with an AUC of 0.717. However, most algorithms provided a greater net benefit than the traditional prediction scores. Machine learning (ML) algorithms developed with routinely available variables could offer beneficial insights for predicting mortality in AIS patients undergoing EVT.
期刊介绍:
Aims
Bioengineering (ISSN 2306-5354) provides an advanced forum for the science and technology of bioengineering. It publishes original research papers, comprehensive reviews, communications and case reports. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. All aspects of bioengineering are welcomed from theoretical concepts to education and applications. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. There are, in addition, four key features of this Journal:
● We are introducing a new concept in scientific and technical publications “The Translational Case Report in Bioengineering”. It is a descriptive explanatory analysis of a transformative or translational event. Understanding that the goal of bioengineering scholarship is to advance towards a transformative or clinical solution to an identified transformative/clinical need, the translational case report is used to explore causation in order to find underlying principles that may guide other similar transformative/translational undertakings.
● Manuscripts regarding research proposals and research ideas will be particularly welcomed.
● Electronic files and software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.
● We also accept manuscripts communicating to a broader audience with regard to research projects financed with public funds.
Scope
● Bionics and biological cybernetics: implantology; bio–abio interfaces
● Bioelectronics: wearable electronics; implantable electronics; “more than Moore” electronics; bioelectronics devices
● Bioprocess and biosystems engineering and applications: bioprocess design; biocatalysis; bioseparation and bioreactors; bioinformatics; bioenergy; etc.
● Biomolecular, cellular and tissue engineering and applications: tissue engineering; chromosome engineering; embryo engineering; cellular, molecular and synthetic biology; metabolic engineering; bio-nanotechnology; micro/nano technologies; genetic engineering; transgenic technology
● Biomedical engineering and applications: biomechatronics; biomedical electronics; biomechanics; biomaterials; biomimetics; biomedical diagnostics; biomedical therapy; biomedical devices; sensors and circuits; biomedical imaging and medical information systems; implants and regenerative medicine; neurotechnology; clinical engineering; rehabilitation engineering
● Biochemical engineering and applications: metabolic pathway engineering; modeling and simulation
● Translational bioengineering